Trial Profile
A Double Blind, Placebo-controlled, Dose-escalating, Multiple Dose Study, Investigating the Safety, Antiretroviral Activity, Tolerability and Pharmacokinetic Profile of Deferiprone When Administered in Healthy Volunteers and Asymptomatic HIV Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ApoPharma
- 21 Jul 2014 New trial record